<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Role of mitochondrial uncoupling protein-4 in energy supply during neuronal differentiation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Ho, PWL; Ho, JWM; So, DHF; Liu, H; Chan, KH; Ramsden, DB; Ho, SL</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>The 16th Medical Research Conference (MRC 2011), Hong Kong, 22 January 2011. In Hong Kong Medical Journal, 2011, v. 17 suppl. 1, p. 31, abstract no. 43</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2011</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/169953">http://hdl.handle.net/10722/169953</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>Hong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
**Role of mitochondrial uncoupling protein-4 in energy supply during neuronal differentiation**

PWL Ho1,2, JWM Ho1, DHF So1, HF Liu1, KH Chan1,2, DB Ramsden1, SL Ho1,2

1Department of Medicine, The University of Hong Kong, Hong Kong
2Research Centre of Heart, Brain, Hormone & Healthy Aging (HBHA), The University of Hong Kong, Hong Kong

**Objectives:** Neuronal differentiation is involved in brain development. Stimulation of all-trans-retinoic acid (RA) in neuroblastoma cells results in growth inhibition, increased neuron-specific enolase (NSE) activity, and promoted axonal growth. Mitochondrial uncoupling protein-4 (UCP4) is specifically expressed in brain. UCP4 overexpression is neuroprotective against mitochondrial dysfunction by increasing ATP supply. We aimed to determine changes of UCP4 expression, and its role in modulating energy supply during neuronal differentiation.

**Methods:** We stably overexpressed human UCP4 in SH-SY5Y cells. Neuronal differentiation was induced by RA for 14 days in both UCP4 overexpressing and vector control cells. Neurite growth was visualised by immunostaining of neuronal tubulin (Tuj1), and changes in UCP4 expression were determined by Western blot. Number of neurite-bearing cells and neurite length were determined by confocal microscopy. The total ATP levels were measured by luciferase bioluminescent assay.

**Results:** Treatment of RA for 14 days induced neuronal differentiation in SH-SY5Y cells, as visualised by morphological changes and induction of neurite projection. The lengths of neurites in UCP4 overexpressing cells were significant longer compared with the controls. During the time course, UCP4 expression was gradually increased in parallel with Tuj1. The pattern of changes of ATP levels in both UCP4 overexpressing and vector cells were similar. However, the ATP level in UCP4 overexpressing cells was consistently higher than the controls.

**Conclusions:** This study revealed potential role of UCP4 in promoting neuronal differentiation, possibly via increasing energy supply. Higher ATP level in UCP4 overexpressing cells is likely rendering the cells better energy supply for the differentiation processes. Knowledge in UCP4 which modulate neuronal energy supply and differentiation has shed light on potential cell therapies against various neurodegenerative diseases.

**Acknowledgements:** This project was financially supported by the Henry G Leong Professorship in Neurology (SL Ho), Research Grants Council, Hong Kong (HKU 7661/07M; SL Ho), the Donation Fund for Neurology Research (SL Ho), and Seed Funding for Basic Research, Committee on Research and Conference Grants (CRCG, HKU 200901159008; PWL Ho).

---

**A pharmacological inhibitor of adipocyte fatty acid binding protein as a potential therapeutic agent for non-alcoholic fatty liver disease**

RL Hoo1,2, J Wong1,2, A Xu1,2, KS Lam1,2

1Department of Medicine, The University of Hong Kong, Hong Kong
2Research Centre of Heart, Brain, Hormone, and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong

**Background:** Obesity is a major risk factor for non-alcoholic fatty liver disease (NAFLD). Our recent study showed that circulating level of adipocyte fatty acid binding protein (A-FABP) is elevated in patients with NAFLD and correlated with hepatic inflammation and fibrosis. We also demonstrated that both acute and chronic liver injuries are accompanied by elevated A-FABP expression in Kupffer cells. This study aimed to examine whether pharmacological inhibition of A-FABP acts as a promising strategy for the treatment of NAFLD using a diet-induced obese mouse model.

**Methods:** C57 male mice were fed with a high-fat high-cholesterol (HFHC) diet to induce chronic liver injury and administered with an A-FABP selective inhibitor, BMS309403 (BMS), for 16 weeks. Serum alanine aminotransferase (ALT), aspartate transaminase (AST), triglyceride and cholesterol levels, and hepatic fat content, were measured by biochemical methods. Quantitative-PCR was performed to determine the hepatic expression levels of A-FABP and several pro-inflammatory cytokines, as well as endoplasmic reticulum (ER) stress and fibrotic markers. H&E staining and oil red O staining were performed to determine the inflammatory status and necrosis in the liver.

**Results:** Oral administration of BMS alleviated glucose intolerance, insulin resistance and liver injury in HFHC-diet–induced obese mice. Treatment with BMS markedly reduced the hepatic expression of pro-inflammatory cytokines (TNF-alpha, MCP-1, IL-6), endogenous A-FABP, fibrotic (pro-collagen and TIMP-1) and ER stress (CHOP, GRP78 and XBP-1) markers. H&E staining and oil red O staining indicated alleviation of the inflammatory status and steatosis.

**Conclusion:** A-FABP may play an aetiological role in obesity-induced NAFLD by inducing ER stress and inflammation. The selective inhibitor of A-FABP may represent a promising drug candidate for the treatment of NAFLD.

**Acknowledgement:** This study was supported by a GRF grant (#768209) from the RGC, Hong Kong.